This appears to be another case of trying to make an eagle out of two turkeys. I’ve previously commented on Labopharm’s pathetic drug portfolio (especially Oleptro), so I won’t repeat that info here. The buyout values DDS.TO (net of cash on hand) at about $15M and is a 68% premium to yesterday’s closing price.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.